← Back to Screener
Design Therapeutics, Inc. Common Stock (DSGN)
Price$10.44
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)17.23%
Price vs S&P 500 (4W)-26.17%
VGM Score61.57
Market Capitalization$654.55M
All Metrics
Book Value / Share (Quarterly)$3.49
P/TBV (Annual)0.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.87
Price vs S&P 500 (YTD)0.79%
EPS (TTM)$-1.19
10-Day Avg Trading Volume1.92M
EPS Excl Extra (TTM)$-1.19
EPS (Annual)$-0.88
ROI (Annual)-20.65%
Cash / Share (Quarterly)$3.57
ROA (Last FY)-19.83%
EBITD / Share (TTM)$-1.34
ROE (5Y Avg)-19.54%
Cash Flow / Share (Annual)$-0.90
P/B Ratio3.00x
P/B Ratio (Quarterly)3.05x
Net Income / Employee (Annual)$-925,900
ROA (TTM)-31.29%
EPS Incl Extra (Annual)$-0.88
Current Ratio (Annual)17.14x
Quick Ratio (Quarterly)22.05x
3-Month Avg Trading Volume0.54M
52-Week Price Return161.35%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.09
P/S Ratio (Annual)2845.87x
Asset Turnover (Annual)0.01x
52-Week High$17.25
EPS Excl Extra (Annual)$-0.88
CapEx CAGR (5Y)19.26%
26-Week Price Return33.16%
Quick Ratio (Annual)16.97x
13-Week Price Return-1.87%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.28x
Enterprise Value$641.78M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3600.00%
Cash / Share (Annual)$3.64
3-Month Return Std Dev92.31%
Net Income / Employee (TTM)$-1,291,000
ROE (Last FY)-20.65%
EPS Basic Excl Extra (Annual)$-0.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.19
ROI (TTM)-33.07%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.86
Price vs S&P 500 (52W)133.14%
Year-to-Date Return11.73%
5-Day Price Return-4.47%
EPS Normalized (Annual)$-0.88
ROA (5Y Avg)-18.65%
Net Profit Margin (Annual)-3600.00%
Month-to-Date Return-22.94%
Cash Flow / Share (TTM)$-1.28
EBITD / Share (Annual)$-1.08
Operating Margin (Annual)-3621.74%
ROI (5Y Avg)-19.54%
EPS Basic Excl Extra (TTM)$-1.19
P/TBV (Quarterly)0.44x
P/B Ratio (Annual)2.51x
Book Value / Share (Annual)$3.52
Price vs S&P 500 (13W)-11.62%
Beta1.65x
Revenue / Share (TTM)$0.00
ROE (TTM)-33.07%
52-Week Low$3.33
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.29est. -0.33
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.09
4.09
4.33
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DSGNDesign Therapeutics, Inc. Common Stock | — | — | B | $10.44 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC molecules, a proprietary platform of small-molecule therapeutics designed to treat inherited diseases caused by nucleotide repeat expansions such as Friedreich Ataxia, Myotonic Dystrophy, Huntington's Disease, and Fuchs Endothelial Corneal Dystrophy. The company's GeneTAC candidates are designed to address the underlying genetic causes of these conditions, offering potential disease-modifying treatments for currently incurable genetic disorders.